Trigger point injection therapy in the management of myofascial temporomandibular pain

Temporomandibular miyofasyal ağrılarda tetik noktası enjeksiyonu tedavisi

Fatih ÖZKAN,¹ Nilüfer ÇAKIR ÖZKAN,² Ünal ERKORKMAZ³

Summary

Objectives: Myofascial pain is the most common temporomandibular disorder. The objective of this study was to compare the effectiveness of combined treatment modalities in the management of myofascial temporomandibular pain.

Methods: Fifty patients (44 female, 6 male) clinically and radiologically diagnosed with myofascial temporomandibular disorder (TMD) were selected for the study and randomly assigned to two groups of 25 patients. Group 1 patients were treated with stabilization splint (SS) and Group 2 patients were treated with trigger point injection combined with SS therapy.

Results: Positive improvement in overall signs and symptoms with statistically significant differences was observed in both groups. Group 2 showed significant reduction in visual analogue scale (VAS) scores, and statistical analysis revealed a significant difference between the VAS scores of Group 1 and Group 2 at the 4th and 12th weeks of treatment follow-up (p<0.001).

Conclusion: Our results indicate that trigger point injection therapy combined with splint therapy is effective in the management of myofascial TMD pain. Further research, especially randomized controlled trials, should be carried out to ascertain its effectiveness over other treatment modalities.

Key words: Myofascial temporomandibular disorder; treatment modalities; trigger point injection.

Özet


Gereç ve Yöntem: Klinik ve radyolojik olarak miyofasyal temporomandibular bozukluk tanı ile 50 hasta (44 kadın, 6 erkek) çalışmaya alındı. Rastgele olarak her iki grupta 25 hasta olacak şekilde iki gruba ayrıldı. Grup 1 stabilizasyon splinti (SS) ile, Grup 2 ise SS tedavisini ve tetik noktası enjeksiyonu ile tedavi edildi.

Bulgular: Her iki grupta genel bulgular ve belirtiler arasında istatistiksel olarak önemli farklar bulundu. VAS skorlarında Grup 2'de önemi azalma görüldü ve istatistiksel analiz sonucu tedavinin 4. ve 12. haftasında yapılan değerlendirmelerde Grup 1 ve Grup 2 arasında VAS skorları açısından önemli farklar bulundu (p<0.001).

Sonuç: Bizim sonuçlarımız miyofasyal temporomandibular bozuklukları splint tedavisinde kombine edilen tetik noktası enjeksiyon tedavisinin etkili olduğunu gösterdi. Özellikle bu yöntem diğer tedavi yöntemleri üzerine etkinliğini belirlemek için daha fazla sayıda randomize kontrollü çalışma yapılmalıdır.

Anahtar sözcükler: Miyofasyal temporomandibular bozukluk; tetik noktası enjeksiyonu, tedavi yöntemleri.
Introduction

Temporomandibular disorder (TMD) is the general term used to describe the manifestation of pain and/or dysfunction of the temporomandibular joint (TMJ) and associated structures.[1]

Myofascial pain is the most common temporomandibular disorder. There are many synonyms for this condition including TMJ dysfunction syndrome, craniofacial pain dysfunction, myofascial pain dysfunction syndrome (MPDS).[2]

In the head and neck region, myofascial pain syndrome with trigger points can manifest as tension headache, tinnitus, TMJ pain and torticollis. A trigger point (TrP) is a focus of hyperirritability in a tissue that, when compressed is locally tender and hypersensitive and gives rise referred pain a tenderness. Although the pain occurs most often in the region over the TrP, pain can be referred to areas distant from the trigger points (TrPs). TrPs may be relieved through noninvasive measures, such as spray and stretch, transcutaneous electrical stimulation, physical therapy, and massage. Invasive treatments for myofascial trigger points include injections with local anesthetics, corticosteroids or botulism toxin, or dry needling. Precise injections into the trigger points are vital in helping deactivate them.[3]

The primary goal in treatment of myofascial temporomandibular pain is to alleviate pain and/or mandibular dysfunction. Many different therapies - some conservative and reversible, others irreversible, including surgery have been advocated for patients with MPDS.[4] A number of successful treatment outcomes have been reported, including occlusal splints, physiotherapy, muscle relaxing appliances, stress-reduction techniques and pharmacotherapy. Various types of occlusal splints have been used in the management of MPDS. The stabilization splint (SS), one such type of occlusal splint, is a hard acrylic splint that provides a temporary and removable ideal occlusion. It reduces abnormal muscle activity and produces neuromuscular balance.[5,6] TrP injection has been shown to be other effective treatment option in management of the MPDS. While relatively few controlled studies on TrP injection have been conducted, this therapy has become widely accepted. These therapies may be used as sole treatment, but use of combined approach has been found more effective by some authors in the literature.[4,7]

To our knowledge, in the literature any other investigation which compared SS therapy and TrP injection therapy is not reported. The objective of the present study was to evaluate the effectiveness of combined treatment modalities in the management of myofascial temporomandibular pain. Therefore, we compared conventional SS therapy with TrP injection combined with SS therapy.

Materials and Methods

After the study was approved by the local ethic committee, the subjects were informed about the study procedure and written informed consent was obtained. The subjects were selected from TMD patients referred to the Clinic of Oral and Maxillofacial Surgery over a period of Jun 2006 to April 2008. Patients suspected to have a dominant muscular disorder and myofascial pain of all degrees of severity were included. The clinical diagnosis was myofascial pain according to the Research Diagnostic Criteria for TMD.[8] Inclusion criteria were pain of muscular origin with or without limited opening, duration of pain at least 3 months including a complaint of pain associated with localized areas of tenderness to palpation in masticatory muscles, combined with self-assessed myofascial pain of at least 40 mm on a 100-mm visual analogue scale (VAS).

To exclude odontogenic reasons for the orofacial pain, a panoramic radiographic evaluation was performed for all patients. Patients with evidence of bone pathology (rheumatoid arthritis, osteoarthritis, condylar resorption) and who had TMJ pain, previous treatment for TMD, use of complete dentures were excluded. Another cases such as trigeminal neuralgia, atypical facial pain were also excluded from this study.

One clinician performed the screening, history-taking, clinical examination including recording the maximal incisal opening (MIO), pain during mandibular movements, noting joint noises and locking, lateral and posterior tenderness of the TMJ. TMJ, masticatory muscles were palpated for TrPs.
Tenderness of the muscles of mastication were assessed by means of digital palpation and functional manipulation. The questionnaire used before and after the treatment included questions about pain frequency, intensity and duration. Intensity rates of pain were recorded on a VAS, 100-mm long continuum. The tenderness in the muscle and the number of the TrPs was recorded as being present or absent. The clinical examination, performed before and after treatment by the same examiner. Another specialist who was not involved in the examination at baseline and at follow-up delivered and adjusted the appliance and TrP injections were performed by pain specialist.

Groups: Fifty patients clinically and radiologically diagnosed with temporomandibular myofascial pain were selected for the study and randomly assigned to two equal Group 1 (21 female, 4 male) and Group 2 (23 female, 2 male) consisting of 25 patients each. The mean ages of the patients were (30.36±8.94 years in group 1) and (30.4±9.22 years in group 2) in respectively.

Group 1: These patients were treated with SS. An upper impression was taken at first visit and SS was made with hard acrylic (Figure 1). At the second visit SS was adjusted. Patients were instructed to wear the splint at night for a period of three months. Patients recalled for splint control one week later.

Group 2: These patients were treated with TrPs injection in combination with SS therapy. TrP injections were applied into the affected masseter (22 injections), temporalis (13 injections) and lateral pterygoid muscles (20 injections).

Technique: The area of maximum tenderness was identified within the affected muscle. After antiseptic preparation of the skin, the muscle was stabilized between the thumb and forefinger. A small gauge needle was introduced into the TrP. The patient was asked about the location and intensity of the pain evoked by needle placement. Local anesthetic solution of 0.5 ml lidocaine + 0.5 ml saline was then injected into the TrP. Injections were repeated three times with two days interval. Pressure was then applied to the injected area for local hemostasis. At first and second visit, local anesthetic + saline mixture, at third visit 0.1 ml triamcinolone acetanide injection was applied.

The patients were recalled for examination 2 week, 4 week and 12 week later after SS and TrP injections were completed. During each visit the patients were asked for their subjective assessment of pain according to VAS scale.

Statistical Analysis
The Chi-square Test was used for comparison of the categorical variables between the two groups. Marginal Homogenity Test was used to determine the difference of categorical variables between before and after the treatment. Categorical variables were presented as number and percentage. Two Independent Samples t-test was used for comparison of the continuous variables between the two groups. Two Dependent Samples t-test was used to determine the significance of differences of continuous variables between before and after the treatment within the groups.

The VAS scores between the groups were compared with the Independent Samples t-test. One-way ANOVA was used for the comparison of VAS scores within the groups. Two-way ANOVA was used for the comparison of the variation of VAS scores between the groups. P value <0.05 was considered statistically significant. Analyses were performed using commercial software (PASW v.18, SPSS Inc, Chicago, IL).
Results

Table 1 shows the comparison of different variables measured between the two groups at the time of diagnosis and at 12 week follow-up. Positive treatment outcomes were found in both groups at the follow-up for signs and symptoms. In both groups, significant reduction was found in the frequency of pain and intensity of pain (p<0.001). The number of TrPs of the masticatory muscles was decreased with statistical significant difference (Group 1 p=0.004, Group 2 p<0.001). Statistically significant reduction were found in the number of patients myofascial pain at rest (Group 1 p=0.001, Group 2 p<0.001) and during mandibular movements (p=0002 in group 1 and p<0.001 in Group 2). In addition, there were statistically significant differences between the groups after the treatment for signs and symptoms, pain during mandibular movements (p=0.005), number of TrP (p=0.001) and intensity of pain (p=0.004), in respectively. Improvement of overall subjective symptoms was reported by all patients in both groups, with a statistically significant difference between the groups (p=0.033), (Table 1).

MIO was presented as mean±standard deviation in both groups at the time of diagnosis and follow-up period. MIO showed a little more increase in Group 2 (36.6±1.7, 40.1±1.6) compared to Group 1 (37.5±2.38, 39.9±1.7) during the three months follow-up. However, this increase was found statistically significant (in both groups p<0.001), but, there was not statistically significant difference between the two groups (p=0.7). VAS scores for pain intensity showed significant reduction in both groups (p<0.001). Statistically significant difference was found in the variation of VAS scores between

| Table 1. The comparison of different variables between the two groups |
|--------------------------|------------------|------------------|-----------------|--------|
| Signs and symptoms       | Before           | After            |                  | p      |
|                         | Group 1 n=25 (%) | Group 2 n=25 (%) | Group 1 n=25 (%)| Group 2 n=25 (%) |
| Frequency of myofascial pain |                  |                  |                  |        |
| Never                   | 0                | 0                | 8 (32)           | 14 (56) |
| Occasionally            | 1 (4)            | 0                | 4 (16)           | 1 (4)  |
| Once a week             | 5 (20)           | 4 (16)           | 2 (8)            | 0      |
| Twice a week            | 19 (76)          | 21 (84)          | 0                | 0      |
| Pain at rest            | 17 (68)          | 18 (72)          | 5 (20)           | 1 (4)  |
| Pain during mandibular movements | 23 (92) | 24 (96)          | 12 (48)          | 2 (8)  |
| Masticatory muscles     |                  |                  |                  |        |
| 0                       | 0                | 0                | 3 (12)           | 9 (36) |
| 1-3 trigger point       | 5 (20)           | 4 (16)           | 9 (36)           | 14 (56) |
| ≥4 trigger point        | 20 (80)          | 21 (84)          | 13 (52)          | 2 (8)  |
| Intensity of myofascial pain |                  |                  |                  |        |
| No pain                 | 0                | 0                | 3 (12)           | 12 (48) |
| Slight                  | 1 (4)            | 0                | 17 (68)          | 13 (52) |
| Moderate to severe      | 16 (66)          | 14 (56)          | 4 (16)           | 0      |
| Severe or very severe   | 8 (32)           | 11 (44)          | 1 (4)            | 0      |
| Improvement of subjective symptoms |              |                  |                  |        |
| Beter                   | 0                | 0                | 20 (87)          | 13 (54.2) |
| Much better             | 0                | 0                | 3 (13)           | 11 (45.8) |
| Reciprocal clicking     | 13 (52)          | 14 (56)          | 12 (10)          | 11 (10) |

TEMMUZ - JULY 2011
the groups \((p=0.003)\). Group 2 showed significant reduction in VAS scores and statistical analysis revealed significant difference between VAS scores of Group 1 and Group 2 at 4 week and 12 week follow-up period \((p<0.001)\) (Table 2), (Figure 2).

**Discussion**

TMDs are principally musculoskeletal, orthopedic and neurologic in nature. In this view various treatment modalities for these patients have been tried and tested over time. Myofascial pain is the most common temporomandibular disorder. Choosing a specific conservative treatment modality for TMJ dysfunction syndrome patients depends on clinicians expertise, patient presentation and elimination of possible etiologic factors. In our case series, patients were considered to belong to the category of myofascial TMD based on clinical diagnosis. No significant difference was observed between Group 1 and Group 2 for the distribution of clinical signs and symptoms. There were no patients in our series who presented with clicking or joint noise alone without tenderness around the TMJ and the associated masticatory muscles.

Various treatment modalities for TMD have been tried and tested. The use of combined approach has been found by some authors to result in more rapid symptom relief, decreased treatment time and overall superior therapeutic outcome in the treatment of myofascial TMD pain. Till date, no single treatment modality has been found more successfull than any combined therapy. In the present study, we evaluated the efficacy of T\(\)rP injection therapy combined with occlusal splint therapy in the management of myofascial TMD pain.

Occlusal splint therapy is commonly used conservative treatment modalities and is useful in the reduction of pain and tenderness in the muscles in MPDS patients. Generally, the conclusions of randomised controlled trials themselves regarding treatment outcome have been positive. Dao and Lavigne (1998) and Turk et al. (1993) found positive treatment outcome with SS therapy in patients suffering from myofascial TMD pain. Ekberg et al. (2003) reported positive efficacy of stabilization appliance on the intensity of myofascial pain, pain during mandibular movements, maximal opening capacity and the number of trigger points of the masticatory muscles. However, Raphael et al. (2003) conclude that oral splints were of modest value for patients with myofascial face pain in their overall sample. Results of our study agree with various studies supporting the usefulness of occlusal splints in the management of TMJ dysfunction.

**Table 2. VAS scores of Group 1 and Group 2**

<table>
<thead>
<tr>
<th></th>
<th>Group 1 (n=25)</th>
<th>Group 2 (n=25)</th>
<th>T</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean±SD</td>
<td>Mean±SD</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain intensity VAS (mm)</td>
<td>Before</td>
<td>7.20±1.50</td>
<td>7.48±1.71</td>
<td>0.62</td>
</tr>
<tr>
<td></td>
<td>2 week follow-up</td>
<td>5.83±1.27</td>
<td>4.92±1.44</td>
<td>2.35</td>
</tr>
<tr>
<td></td>
<td>4 week follow-up</td>
<td>4.64±1.25</td>
<td>3.00±1.12</td>
<td>4.88</td>
</tr>
<tr>
<td></td>
<td>12 week follow-up</td>
<td>3.16±1.52</td>
<td>1.40±1.16</td>
<td>4.61</td>
</tr>
</tbody>
</table>

\(F=96.71, \text{p}<0.001\*) \quad F=172.31, \text{p}<0.001\*) \quad F=9.74, \text{p}=0.003\)

**Figure 2.** Mean VAS scores of Group 1 and Group 2 at the time of diagnosis and follow-up.
syndrome. But, our results showed that TrP injection combined with SS therapy was more effective in the treatment of myofascial TMD pain for signs and symptoms improvement.

Naikmasur, et al. (2008) and Suvinen and Reade (1989) have also shown 10.02 mm and 7.4 mm increase in MIO after splint therapy in MPDS patients. Wong and Cheng (2003) achieved normal mouth opening (MIO ≥40 mm) in their patients by the end of treatment with combination of acupuncture+SS+point injection therapy. Similarly, we achieved normal mouth opening (mean=40.12 mm) at the end of the treatment follow-up in Group 2.

In our study, it was observed significant and progressive reduction in VAS scores and the number of tender points during three months treatment follow-up in Group 1. Raphael et al. (2003) have also found that occlusal splints had decreased the VAS scores and the number of painful muscles in during a six-week follow-up study in patients with myofascial pain. This is in agreement with our conclusions. Turk et al. (1993) found that significant short-term effect on pain, comparing an intraoral appliance with biofeedback/stress management in TMD. Naikmasur et al. (2008) imply that the occlusal splint causes a slow and steady improvement in TMJ symptoms. Dao and Lavigne (1998) and Ekberg et al. (2003) concluded that oral splints should be used as an adjunct for pain management rather than as a specific treatment modality. TMD tends to be a chronic recurrent pain condition therefore, patients with myofascial pain in general should be treated with more effective treatment regimen.

Our patients in Group 2 experienced a decrease in the intensity of myofascial pain and a progressive improvement in TMJ symptoms in comparison to Group 1. It was observed in significant reduction in VAS scores during three-month follow-up, especially in the third month of follow-up (p=0.00). This is consistent with the conclusions of Wong and Cheng (2003) who performed point injection for residual TrPs after the acupuncture treatment. It has been established that referred pain to the TMJ and other head and neck locations is commonly result of active trigger points in the muscles of mastication, sternocleidomastoid, cervical and trapezius muscles. In our opinion, the improvement of symptoms in Group 2 may indicate that referred pain from the TMJ and associated structures decreased as a result of myofascial TrP injection therapy. The number of patients with ≥4 tender points of the masticatory muscles significantly decreased in TrP Group. Presence of TrPs after the point injection may be resulted from unsuccessful injections or the medial pterygoid muscle can not be injected.

Both invasive and non-invasive techniques have been used in the treatment of myofascial TrP pain. Gül and Önal (2009) compared non-invasive techniques with invasive techniques in patients with myofascial pain syndrome. They reported that TrP injection with lidocaine or botulinum toxin-A provided better pain control when compared to non-invasive techniques such as laser and transcutaneous electrical nerve stimulation in patients with myofascial pain syndrome. However, Baldry (2002) suggested that superficial dry needling (SDN) to be sufficient in the treatment of myofascial TrP pain and if the response to SDN is inadequate, more invasive approach should be considered. With respect to point injection it is reported that the nature of the injected substance makes no difference to the outcome. TrP injection therapy is a painful application and appears to have a little effect on improvement of joint noises. But, it seems to have a more rapid pain relief and decrease treatment time in patients with myofascial TMD pain, which is the chief complaint of most patients seeking therapy.

Goals of treatment TMJ dysfunction syndrome include reducing or eliminating pain, restoring normal jaw function. Simple cases can be managed by a single clinician with self-care, exercises and SS therapy. But complex patients should be managed most effectively within a interdisciplinary clinic setting that uses a team of clinicians to address different aspects of the problem in a concerted fashion. To improve outcomes, it is important to match the level of complexity of the management program and to distinguish between joint disorders and muscle disorders in TMD patients. Therefore, a careful evaluation of TrPs is useful for a correct interpretation of the orofacial muscular pain in TMD patients and
these patients should be managed with multidisciplinary approach.[3,24-26]

**Conclusion**

The results of this study indicate that TrP injection therapy, in combination with splint therapy is more effective than splint therapy alone for management of TMD. But, the present study have certain limitations like the absence of a control group without therapy, it was impossible to determine other factors (such as psychologic, placebo, spontaneous remission) could have contributed to treatment outcome. It is also difficult to compare our results with the literature, because of the lack of the studies comparing an intraoral appliance with point injection therapy in TMD. Therefore, further research, especially randomised blinded controlled trials, should be carried out to ascertain its effectiveness over other combined treatment modalities. There is need to studies comparing different treatment modalities in myofascial TMD pain.

**References**